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Abstract
Background: In the last few years several indices and tools, aimed at identifying frail subjects in various care
settings have been developed. However, to date none of them has been incorporated into usual practice in the
primary care setting. The purposes of this study are: 1) to evaluate the predictive capacity of the Tilburg Frailty
Indicator (TFI), the Gérontopôle Frailty Screening Tool (GFST) and the KoS model together with two biomarker
levels (SOX2 and p16INK4a) for adverse events related to frailty; 2) to determine differences in the use of healthcare
services according to frailty.
Methods/Design: Prospective multicentre cohort study with a 2-year follow-up. The study will be performed in
primary care centres of Gipuzkoa and Costa del Sol, both located in Spain. Autonomous, non-institutionalized
individuals aged 70 and over that agree to participate in this study will constitute the study population. A total of
900 individuals will be randomly selected from the healthcare administrative data bases of the participating health
services. Data will be collected at baseline and at 1 and 2 years. The main independent variables assessed at
baseline will be TFI outcomes, GFST and the KoS model, together with the expression of SOX2 and p16INK4a levels.
During follow-up, loss of autonomy, the occurrence of death and consumption of healthcare resources will be
assessed.
Discussion: The main focus of this work is the identification and evaluation of several instruments constructed
under different rationales to identify frail subjects in primary care settings. The resulting outcomes have potential
for direct application to the primary care practice. Early identification of the onset of functional impairment of
elderly is an essential, still unresolved aspect in the prevention of dependence in the scope of primary care.
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Background
Ageing is accompanied by a series of physiological changes
which lead to a gradual loss of adaptation to the demands
of the environment and increased vulnerability. The most
severe expression of ageing is the clinical condition of frailty
[1]. This is defined by the gradual reduction in resilience
and reserve capacities leading to an overall deterioration in
health. This deterioration can subsequently progress to de-
pendence, intensive use of healthcare resources, and death
[2, 3]. Frailty is a powerful indicator of the state of health of
the elderly [3] but progress needs to be made to understand
the process of frailty, its onset, its determining factors and
consequences [4].
In the last few years several indices and tools aimed at
identifying frail subjects in various care settings have
been developed. However, to date none of them has
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been incorporated into usual practice in a primary care
setting.
Existing instruments
Instruments for the identification of frail individuals are
based on different approaches and rationales [5–7].
Three of them are considered in this study.
1. Instruments based on rules: their construction is
based on multiple regression analysis models. This
group includes, among others: a) The frailty phenotype
model proposed by Fried in 2001, that evaluates the
presence of five criteria: slow walking speed, reduced
grip strength, low physical activity, exhaustion and
unintentional weight loss [2], b) The Tilburg Frailty
Indicator (TFI), that has been considered [5, 8] as the
most suitable to be used in primary care due to its
simplicity and psychometric characteristics [9], and c)
The KoS model, a new model developed by this
investigation group, which considers the age of the
subject, the presence of polipharmacy and the Timed
Up and Go (TUG) test results [10].
2. Instruments based on clinical judgement: these
instruments are designed to classify individuals
based on the clinical history and the clinician’s
knowledge and assessment. Two instruments are
included in this group: a) the Clinical Frailty Scale
(CFS) [11], from the Canadian Study of Health and
Ageing (CSHA) group, and b) the Gérontopôle
Frailty Screening Tool (GFST) [12].
3. Frailty biomarkers: a total of 63 different possible
frailty biomarkers (genes) have been suggested. Most
of these genes are involved in oxidative stress,
inflammation and metabolism although there is no
clear consensus on their validity [13, 14]. Interleukin
6 (IL-6) is probably the most standardised marker
for this purpose [13]. However, it is of major interest
to explore new frailty markers. It is well-known that
ageing is associated with a reduction in the regen-
erative tissue properties. Given that the regenerative
capacity of tissues relies on stem cells, ageing and
frailty may be at least partially, a consequence of a
disorder in stem cell regulation [15]. The transcrip-
tion factor SOX2 (denominated from Sex determin-
ing region Y-related HMG box2) is very important
in the biology of stem cells. Also it is one of the 4
factors necessary to re-programme differentiated
cells in induced pluripotent stem cells [16], to ensure
capacity for self-renovation of this cell population
[16–20] and regulate their de-differentiated state
[16–18]. Surprisingly, its function in tissue and in
the ageing body still needs to be investigated. Inter-
estingly, it is known that its expression reduces in
different brain areas with ageing [19]. These results
indicate that reduced SOX2 levels may be a marker
of the ageing process and is suggested as a possible
biomarker of frailty. Additionally, the tumour sup-
pressor p16INK4a, which is an inhibitor of the cell
cycle progression and an important mediator of cel-
lular senescence has been postulated as a biomarker
of ageing [21, 22] and could also represent an indica-
tor of frailty.
Healthcare resources
Frail subjects present a high rate of adverse events such
as dependence, institutionalisation or death. In the Fried
2001 study the prevalence of hospitalisation of frail pa-
tients was 59 % in the first year compared to 33 % in the
non-frail population [2]. These data lead to the hypoth-
esis that, in our setting, frailty may be associated with a
different pattern of health resources consumption. Frail
individuals are expected to do a more frequent and in-
tensive use of the available healthcare resources.
The goal of this project is to evaluate the predictive
capacity of the TFI, GFST, KoS model, as well as of the
SOX2 and p16INK4a levels for adverse events related to
frailty. An additional objective is to describe the existing
differences in the pattern of healthcare services use ac-
cording to frailty status.
Methods/Design
Design
Prospective multicentre cohort study with a two-year
follow-up of autonomous and community dwelling sub-
jects aged 70 and over.
Scope
The study will be performed in the primary care areas of
Gipuzkoa and Costa del Sol, in the north and south
shores of Spain. At these locations, primary care services
provide care to 384,683 and 473,478 users of whom
11 % are aged 70 and over.
Study population
Autonomous (Barthel test >90 points), not institutiona-
lised individuals (living at their home or with a family
member) aged 70 and over, who agree to participate in
the study. Subjects in a terminal situation defined ac-
cording to the guidelines of the Spanish Society of Pal-
liative Care [23], those who reside more than 6 months
per year in a different area and those with difficulty
communicating in Spanish or Basque (in Gipuzkoa area
only), will be excluded from the study. Patients will be
randomly selected from the administrative databases of
the participating healthcare services. The sample will be
representative of the populations of interest in terms of
age and sex.
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Essential socio-demographic information related to all
patients who comply with the selection criteria will be
collected with the purpose of comparing subjects who fi-
nally participate to those who refuse or abandon. A de-
tailed overview of the planned flow of participants is
provided in Fig. 1.
Variables
The variables collected throughout the study are pre-
sented in Table 1.
Outcome variables
1. The occurrence of adverse events related to frailty,
mainly loss of autonomy, defined as Barthel ≤90
[24]. Death is considered to be an adverse event
associated with frailty, but it is not planned to be
studied as a single outcome as its expected
frequency would not allow it (details in sample size
section). Loss of autonomy and death will be studied
jointly during a secondary analysis phase.
2. The consumption of healthcare resources
considering the number of primary care
consultations by medical and nursing staff, the
number of visits to the emergency department,
number of specialised consultations, number of
hospital admissions and days of stay, number of
admissions in short stay departments.
Main independent variables
– The Tilburg Frailty Index (TFI) is a self-administered
questionnaire that takes 14 min to fill in. It contains
15 items split into three components: physical, psy-
chological and social. It collects information on the
degree of autonomy, cognitive capacity, mood, phys-
ical functionality and social network support. Its
total score ranges from 0 to 15 points. This ques-
tionnaire is being translated and validated in Spanish
by the present investigation group.
– The Gérontopôle Frailty Screening Tool (GFST) is
designed to be administered to people aged 65 and
over, autonomous, without concurrent acute clinical
pathology. It is comprised of an initial questionnaire
guiding the doctor to assess some general signs or
symptoms that could suggest the presence of an
unidentified frailty situation. In a second section the
professional is asked to express their clinical opinion
on the existence of frailty. The final GFST tool
result is based on this very clinical opinion.
– The KoS model is comprised of the individual’s age
at the time of the interview, the presence of
polipharmacy, considered as the consumption of
four or more prescribed medicines and the result of
the TUG test [25]. The KoS model (publication
under review) presents an area under the curve
(AUC) of 0.822.
– The expression of SOX2 and p16INK4a will be
measured in a blood obtained from a subsample of
patients. First, these samples will undergo an RNA
purification by means of the RNeasy Kit (Qiagen).
The RNA will be retro transcribed using the reverse
transcription cDNA High Capacity kit of Applied
Biosystems. Then, the expressions of SOX2 and
p16INK4a will be determined by means of
quantitative PCR (qPCR) using specific primers or
Fig. 1 Study protocol description
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probes and the equipment ABI Prism® SDS 7300
Real Time PCR System from Applied Biosystems.
Expression levels will be standardised with those for
expression of the enzyme Glyceraldehyde-3-
Phosphate Dehydrogenase (GAPDH) and compared
to the IL-6 levels which will be studied in parallel.
Secondary independent variables
– Socio-demographic data: Date of birth, sex, level of
studies, income level and place of residence.
– Healthcare-related lifestyle: 1) Physical activity
measured with the Short Physical Performance
Battery (SPPB), which includes evaluation of
balance, gait speed and getting up and sitting in a
chair [26]. 2) Tobacco consumption: three items
have been included to establish smoking habits
according to the WHO [27]. 3) Screening for
malnutrition, evaluated with the Mini Nutritional
Assessment test [28].
– State of health: 1) Self-perceived health measured
with a single item: “Overall, you would say your
health is…” with five response options: excellent,
very good, good, fair, and poor, 2) Health-related
quality of life evaluated using the EQ-5D question-
naire (EuroQuol Group) [29], 3) Cognitive status with
the Mini Mental State Examination (MMSE) [30], 4)
Existence of geriatric syndromes: visual and auditory
deficits, the occurrence of falls during the year prior
to inclusion, 5) Comorbidity measured by the Cumu-
lative Illness Rating Scale [31] and the Charlson Co-
morbidity Index [32] and 6) Prescription drugs. This
Table 1 Study variables
Domain Variables or Questionnaires Description Assessment
Socio-demographic Date of birth, health centre, sex Baseline
Control Data Date of interview, person interviewed Baseline
Frailty Modified Fried frailty criteria Unintentional weight loss, low level of
physical activity, low energy/tiredness,
muscle weakness, slow movements
Baseline
Tilburg Frailty Index 15 items, 3 domains (physical,
psychological and social)
Baseline
KoS Model Age + Polypharmacy + Timed Up-and-Go test Baseline
Gérontopôle Frailty Screening Tool 6 items + Clinical judgement Baseline
Health-related lifestyle Physical activity - Short Physical
Performance Battery
3 tests: balance, walking speed and
getting up and sitting down from
a chair 5 times
Baseline
Tobacco use 3 items Baseline
Malnutrition screening - Mini Nutritional
Assessment
18 items Baseline
Health Status Self-perceived health 1 item Baseline
Healt-related quality of life - EuroQol 5D 5 items + 0–100 visual analogue scale Baseline
Cognitive state - Mini-cog test 14 items, 5 domains: orientation,
attention, concentration, calculation,
memory, language and construction
Baseline
Geriatric syndromes Sight, hearing and falls Baseline
Comorbidity (I) Review of 10 diseases in clinical record Baseline
Comorbidity (II): Cumulative Illness Rating Scale Review of 19 diseases in clinical record Baseline
Comorbidity (III): Charlson Comorbidity Index Review of 13 diseases in clinical record Baseline
Drug use Assessment of 5 therapeutic groups of drugs Baseline
Functional capacity Basic activities of daily living - Barthel Index 10 items Baseline, 1 year, 2 years
Instrumental activities of daily living -
Lawton & Brody scale
8 items Baseline
Biomarkers 2 markers SOX2 and p16lNK4a Baseline
Health resources use Use of Primary and Specialty Healthcare
Resources
Primary Care, ER, Hospitalization 1 year, 2 years
Adverse events Loss of autonomy; Death 1 year, 2 years
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information will be collected by means of personal in-
terviews and from the clinical records.
– Functional autonomy and capacity: reflects the
capacity to perform basic and instrumental activities
of daily living. The Barthel Index will be used to
evaluate basic activities and the Lawton and Brody
scale will be used to assess instrumental ones [33].
Sample size
The experience of this investigation group with similar
data, leads to the hypothesis that at the end of follow-up
15 to 20 % of the recruited subjects will have become
dependent according to the defined criteria. Thus, for a
total of 650 subjects it is calculated that 100 to 130 will
present this event. Following the rule of 10 events per
variable for the logistic regression models, the expected
distribution in the two outcome groups (the one present-
ing adverse events related to frailty and the group not pre-
senting them), will allow to construct logistic regression
models considering several indices at the same time, in
case a simultaneous effect is suggested when predicting
the adverse event. It will also enable studying the predict-
ive capacity of categorised indices which generally increase
the requirements of the total N. This N should also allow
for possible subgroup analyses if so indicated by the data.
It is estimated that death will occur in a much lower
percentage, not more than 5 %. Because of its expected
low-frequency, this result will not be studied individu-
ally. In addition, it is expected that approximately 20 %
of the recruited subjects will not attend the arranged ap-
pointment with the study personnel or will not provide
informed consent, and therefore will have to be excluded
from the study. Similarly, another 20 %, will not provide
data at the end of the study for various other reasons.
Considering these follow-up losses the initial sample size
has to be increased by 40 %, recruiting a total of 900
subjects (450 in each setting).
Genetic analyses will be performed in a subsample of
100 subjects (50 in each setting) randomly selected con-
sidering their frailty status measured by the TFI. This
approach is used to ensure the feasibility of the project
given the level of resources required to perform the gen-
etic expression analyses proposed.
Data management
All selected subjects will be contacted by letter and phone
and will receive information about the project. Those
interested in participating will undergo the Barthel test.
Subjects with a Barthel ≤90 will be excluded. Basic socio-
demographic data of subjects who decline participation
will be collected and analysed with the purpose of identi-
fying possible selection or participation bias.
Those interested will be informed in detail about the
study; will sign an informed consent and will undertake
a baseline assessment performed by a trained nurse.
Blood samples will be extracted in the selected sub-
sample. Information on current clinical diagnoses and
consumption of medicines will be obtained from the
clinical records.
The variables related to the use of healthcare resources
will be obtained from the electronic clinical records and
the administrative databases of the healthcare services.
Autonomy status will be assessed with the Barthel test at
1 and 2 years through a telephone interview. The event
of death will be checked on clinical records.
Statistical analysis plan
The study unit is the patient. Categorical variables will be
described with frequencies and percentages and continu-
ous variables with means and standard deviations (SD) or
medians and interquartile ranges (Q1, Q3), according to
their degree of symmetry. Categorical variables will be
compared with the chi-square or Fisher’s exact test. Con-
tinuous variables with a Normal distribution will be com-
pared with the Student’s t-test and the non-parametric
Wilcoxon rank-sum test will be implemented for variables
with distributions other than Normal. The following stat-
istical analysis plan will be performed:
1. Association between different indices: The
relationship between the scores of different indices
as well as with biomarkers’ levels will be examined
with the Pearson’s and Spearman’s correlation
coefficients. Point estimates of these correlations and
their 95 % confidence intervals (95 % CI) will be
provided. Concordance between the tests after
categorising patients according to cut-off points
established in the scientific literature will also be ex-
amined. This concordance will be studied with the
Kappa coefficient.
2. Outcome of dependence during follow-up: The
relationship of all implemented indices with
dependence (yes/no) at the end of the study will be
verified. This relationship will be studied by means
of binary logistic regression models. In any case, the
predictive capacity of the indices will be verified
considering them both as continuous and as
categorical variables, according to published
references when available. In case there are no
publications (e.g. SOX2) possible cut-off points will
suggested by means of ROC curves. During this
analysis phase the external validation of the KoS
model, applied to this cohort of subjects, will also be
examined. The predictive effect of each index, both
univariate and multivariate will be studied. The aim
is to study whether the simultaneous consideration
of more than one of the included indices can improve
the prediction of this adverse event and also quantify
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this improvement in terms of AUC, sensitivity and
specificity of the derived probabilities.
3. Differences in terms of resources consumption by frail
and non-frail subjects: Frequency of consumption as
well as duration of possible hospital admissions will
be compared between the two groups. These data
usually follow skewed distributions therefore
comparisons will most likely be performed by means
of median differences. Confidence intervals will be
estimated and non-parametric statistics will be used
in these cases.
All statistical analyses will be performed with the SAS
9.3 and the R 3.1.0 software.
Discussion
The priority of frailty in the context of research in health-
care services is highlighted, among others, by the European
Commission report on ageing (2012) which specifies that
“the reduction of disability and dependence by means of
appropriate measures in the frailty process should be at the
forefront of innovation in all healthcare policies” [34].
This project is aimed to increase the evidence of
suitable instruments able to identify frail subjects in
primary care settings and to study the use of health-
care services of these subjects. The identification of
frail subjects is highly relevant because it can help to
design interventions adapted to their needs, which in
turn could help stopping or at least delaying the nat-
ural advance towards dependence. Primary care is the
most appropriate setting to identify frail individuals
because of its proximity and accessibility [35]. In this
healthcare setting, the identification of frailty should
be simple and require little time [36].
The main limitation of this work is related to the pos-
sibility of having a representative sample of the non-
dependent elderly population in our setting given the
tendency of subjects with better heath to be more likely
to participate. This can limit the incidence of adverse
events sought during follow-up. For this reason, a sam-
ple of advance age was selected in which the likelihood
of occurrence of these events is greater.
Another limitation is the expected rate of losses to
follow-up. To reduce these losses, contact data will be
verified and additional contacts (carer, spouse or descen-
dants) will be requested in order to maintain close con-
tact with the participants.
The main focus of this study is the evaluation of in-
struments and strategies for identifying frail subjects, a
goal that has major potential for direct application on
primary care settings. Early identification of the onset of
functional impairment in elderly subjects is an essential
but still unresolved aspect in the prevention of depend-
ence. The final goal of this study is to offer to the
scientific community a suitable instrument to identify
frail individuals in the primary care setting.
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